Sugi Predict

Sugi Predict / Compounds / SCHEMBL20845751

SCHEMBL20845751

SCHEMBL20845751

O=C1NC[C@H](c2cccc(Br)c2)O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 2/20 0.41
▸ FFAR1 O14842 3/20 0.38
▸ ABCC9 O60706 1/20 0.38
▸ ABCC8 Q09428 1/20 0.38
▸ KCNJ11 Q14654 1/20 0.38
▸ KCNJ8 Q15842 1/20 0.38
▸ POLB P06746 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MAPT P10636 1/20 0.37
▸ KMT2A Q03164 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ F2RL1 P55085 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2899075 1.00 KDM1A (0.41) KDM1AFFAR1ABCC9ABCC8KCNJ11
SCHEMBL5021997 0.81 MEN1 (0.44) ALDH1A1KMT2AMEN1HTR2C
SCHEMBL5021614 0.81 GRM5 (0.42) KDM4EALDH1A1KMT2AMEN1
SCHEMBL10242047 0.81 SLC6A3 (0.51) ALDH1A1HPGDTSHRMAPT
SCHEMBL30669254 0.81 GRM5 (0.42) KDM4EALDH1A1KMT2AMEN1
SCHEMBL2896669 0.80 DDB1 (0.40) KDM1APOLBALDH1A1HPGDKMT2A
SCHEMBL20840267 0.80 DDB1 (0.40) KDM1APOLBALDH1A1HPGDKMT2A
SCHEMBL2899162 0.79 HSD17B10 (0.47) KDM4EALDH1A1HPGDTSHR
SCHEMBL4429 0.79 HSD17B10 (0.47) KDM4EALDH1A1HPGDTSHR
SCHEMBL8809819 0.79 HSD17B10 (0.47) KDM4EALDH1A1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-12540127-B2 CRBN ligands and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-03 — — US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 — — CN disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 — — CN disclosed
US-20200377469-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2020-12-03 — — US disclosed
EP-3731869-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-11-04 — — EP disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
WO-2019060693-A1 CRBN LIGANDS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2019-03-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM1A 160/4885FFAR1 2115/4885ABCC9 3800/4885
US-20200377469-A1 CRBN LIGANDS AND USES THEREOF CRBN, CRKL, ERBB3 KDM1A 3027/4885FFAR1 4339/4885ABCC9 3977/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM1A 160/4885FFAR1 2115/4885ABCC9 3800/4885
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM1A 160/4885FFAR1 2115/4885ABCC9 3800/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM1A 160/4885FFAR1 2115/4885ABCC9 3800/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM1A 160/4885FFAR1 2115/4885ABCC9 3800/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM1A 160/4885FFAR1 2115/4885ABCC9 3800/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM1A 160/4885FFAR1 2115/4885ABCC9 3800/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM1A 160/4885FFAR1 2115/4885ABCC9 3800/4885
US-12540127-B2 CRBN ligands and uses thereof CRBN, NR2C2, NR2E3 KDM1A 3378/4885FFAR1 1504/4885ABCC9 2577/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM1A 160/4885FFAR1 2115/4885ABCC9 3800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.